XNAS · Healthcare · Biotechnology
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
**Rolling NDA submission initiated** for tinlarebant in Stargardt disease with Q2 completion expected, marking major regulatory milestone for the ophthalmology-focused biotech.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | Q1 2026 | -0.63 | -0.45 | +28.57% | $0 | ✅ Beat | +1.66% | -0.89% | — |
| 2026-03-02 | Q4 2025 | -0.55 | -0.70 | -27.27% | $0 | ❌ Miss | -0.82% | +0.87% | -5.82% |
| 2025-11-10 |
| Q3 2025 |
| -0.51 |
| -0.65 |
| -27.45% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -0.44 | -0.50 | -13.64% | $0 | ❌ Miss | -1.27% | -6.55% | -4.65% |
| 2025-05-13 | Q1 2025 | -0.37 | -0.45 | — | $0 | ❌ Miss | — | — | — |
| 2025-03-17 | Q4 2024 | -0.31 | -0.32 | -3.23% | $0 | ❌ Miss | — | — | — |
| 2024-11-12 | Q3 2024 | -0.29 | -0.28 | +3.45% | $0 | ✅ Beat | — | — | — |
| 2024-08-09 | Q2 2024 | -0.25 | -0.26 | -4.00% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.